PMID- 34617814
OWN - NLM
STAT- MEDLINE
DCOM- 20211011
LR  - 20211013
IS  - 1473-2300 (Electronic)
IS  - 0300-0605 (Print)
IS  - 0300-0605 (Linking)
VI  - 49
IP  - 10
DP  - 2021 Oct
TI  - Lesion human leukocyte antigen-E is associated with favourable prognosis for 
      patients with oesophageal squamous cell carcinoma.
PG  - 3000605211047278
LID - 10.1177/03000605211047278 [doi]
LID - 03000605211047278
AB  - OBJECTIVE: To investigate the clinical significance of human leukocyte antigen 
      (HLA)-E levels in oesophageal squamous cell carcinoma (ESCC). METHODS: The levels 
      of HLA-E immunostaining in ESCC lesions and 47 corresponding adjacent normal 
      tissues were measured using immunohistochemistry. The correlation between the 
      levels of immunostaining and clinical parameters was analysed. RESULTS: This 
      study analysed 110 paraffin-embedded primary tumour lesions and 47 
      case-controlled paracancerous tissues that were surgically resected from 110 
      patients with ESCC. Positive immunostaining for HLA-E was observed in 88.2% (97 
      of 110) of ESCC lesions and 29.8% (14 of 47) of normal oesophageal tissues. There 
      was no correlation between HLA-E immunostaining in ESCC lesions and 
      clinicopathological characteristics such as lymph node metastasis, 
      tumour-node-metastasis stage and differentiation grade. Kaplan-Meier survival 
      analysis revealed a significantly better prognosis in patients with higher levels 
      of HLA-E immunostaining than in those with lower levels of HLA-E immunostaining; 
      overall survival was 28.6 months (95% confidence interval [CI], 23.2, 34.0) 
      versus 15.3 months (95% CI, 11.5, 19.1), respectively. Furthermore, multivariate 
      analysis showed that the HLA-E level was an independent prognostic factor in 
      patients with ESCC. CONCLUSION: A higher level of HLA-E immunostaining was 
      associated with favourable survival in patients with ESCC.
FAU - Xu, Yong-Fu
AU  - Xu YF
AD  - Department of Hepatobiliary Surgery, Taizhou Hospital of Zhejiang Province 
      Affiliated to Wenzhou Medical University, Linhai, Zhejiang Province, China.
FAU - Du, Xue-Feng
AU  - Du XF
AD  - Department of Hepatobiliary Surgery, Taizhou Hospital of Zhejiang Province 
      Affiliated to Wenzhou Medical University, Linhai, Zhejiang Province, China.
FAU - Li, Zhen-Yu
AU  - Li ZY
AD  - Department of Hepatobiliary Surgery, Taizhou Hospital of Zhejiang Province 
      Affiliated to Wenzhou Medical University, Linhai, Zhejiang Province, China.
FAU - Fang, Zhe-Ping
AU  - Fang ZP
AD  - Department of Hepatobiliary Surgery, Taizhou Hospital of Zhejiang Province 
      Affiliated to Wenzhou Medical University, Linhai, Zhejiang Province, China.
FAU - Zhang, Fa-Biao
AU  - Zhang FB
AUID- ORCID: 0000-0001-5612-414X
AD  - Department of Hepatobiliary Surgery, Taizhou Hospital of Zhejiang Province 
      Affiliated to Wenzhou Medical University, Linhai, Zhejiang Province, China.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
RN  - 0 (HLA Antigens)
SB  - IM
MH  - *Carcinoma, Squamous Cell/diagnosis
MH  - *Esophageal Neoplasms/diagnosis
MH  - *Esophageal Squamous Cell Carcinoma
MH  - HLA Antigens
MH  - Humans
MH  - Prognosis
PMC - PMC8504691
OTO - NOTNLM
OT  - HLA-E
OT  - Human leukocyte antigen
OT  - immune
OT  - oesophageal squamous cell carcinoma
OT  - prognosis
COIS- Declaration of conflicting interest: The authors declare that there are no 
      conflicts of interest.
EDAT- 2021/10/08 06:00
MHDA- 2021/10/12 06:00
PMCR- 2021/10/07
CRDT- 2021/10/07 12:15
PHST- 2021/10/07 12:15 [entrez]
PHST- 2021/10/08 06:00 [pubmed]
PHST- 2021/10/12 06:00 [medline]
PHST- 2021/10/07 00:00 [pmc-release]
AID - 10.1177_03000605211047278 [pii]
AID - 10.1177/03000605211047278 [doi]
PST - ppublish
SO  - J Int Med Res. 2021 Oct;49(10):3000605211047278. doi: 10.1177/03000605211047278.